News Digest / Income Statements / USANA Health Sciences Reports Mixed Q1 2025 Results Amid Growth Challenges and Increased Costs

USANA Health Sciences Reports Mixed Q1 2025 Results Amid Growth Challenges and Increased Costs

StockInvest.us
03:00pm, Tuesday, May 06, 2025
Illustration by StockInvest.us

Company Overview
USANA Health Sciences, Inc. (NYSE: USNA) is a global nutrition, personal health, and wellness company that manufactures science-based nutritional and personal care products. The company operates primarily through two segments: direct selling and the recently acquired Hiya direct-to-consumer segment.

Current Financial Highlights (Q1 2025)
- **Net Sales**: $249.5 million, up 9.5% from $227.8 million in Q1 2024.
- **Net Earnings**: $9.4 million, down 43.1% from $16.5 million in Q1 2024.
- **Earnings Per Share (EPS)**: $0.49, decreased from $0.86 in the prior-year quarter.
- **Gross Profit Margin**: 79.0%, down from 81.1% year-over-year.

Positive Aspects
- Strong revenue growth, particularly from the Hiya segment, which generated $37.1 million in sales for the first time since its acquisition.
- Stable cash reserves at $179.6 million, indicating good liquidity to meet operational needs.

Negative Aspects
- Significant downturn in net earnings, attributed primarily to amortization costs from the Hiya acquisition and decreased direct selling earnings.
- A challenging economic environment resulting in a decline in active Customers from 494,000 to 459,000, a drop of 7.1% year-over-year.
- Increased selling, general, and administrative expenses, up $27.1 million, affecting overall profitability.

Key Financial Statistics:
- **Cost of Sales**: $52.4 million (Q1 2025), compared to $43.1 million (Q1 2024).
- **Operating Expenses**: Increased from $160.1 million to $181.4 million, mainly due to higher selling and administrative costs and promotions.
- **Associate Incentives**: Increased by 40 basis points to 42.4% of segment net sales.
- **Total Liabilities**: $162.7 million, with current liabilities at $137.4 million.
- **Cash Flow from Operations**: $15.5 million in Q1 2025, down from $17.7 million in Q1 2024.

Conclusion
USANA Health Sciences, Inc. faces growth challenges partly due to lower active customer counts in its direct selling segment and increased operational costs post-acquisition of Hiya. The successful integration of Hiya into its business model and the ability to stabilize customer numbers will likely be vital for restoring profitability and boosting share value moving forward.

About The Author

StockInvest.us

StockInvest.us is a stock market research tool that provides daily stock signals and technical analysis for over 25 000 tickers on 38 exchanges. The company was founded in 2016 in Vilnius, Lithuania.

Trusted Broker
Start Your Journey With:
eToro
0% Commission Stock Trading
Follow Other Investors Strategy
Wide variety: Crypto, stocks, ETFs

Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk.